Bioequivalence of gliclazide tablets in Chinese healthy volunteers

Zhen-yan HOU,Miao YAN,Hua-lin CAI,Yang DENG,Yan-qin WU,Si-si CAO,Bi-kui ZHANG
DOI: https://doi.org/10.7539/j.issn.1672-2981.2017.11.005
2017-01-01
Abstract:Objective To determine the pharmacokinetics and bioequivalence of 2 gliclazide tablets in Chinese healthy volunteers.Methods A single-center,randomized,cross-over,two way study design was used.Under fasting conditions,a single oral dose of the test or the reference gliclazide tablets was given to 24 subjects (16 males and 8 females).The plasma concentrations of gliclazide were determined by a high performance liquid chromatography-tandem mass spectrometry.The pharmacokinetic parameters were calculated.Results The main pharmacokinetic parameters of gliclzide in the test and the reference preparations were as follows:tmax was (4.50-±-1.89) h and (4.21±-1.61) h;Cmax was (5959.86± 1251.32) ng·mL-1 and (6003.26± 1357.84) ng·mL-1;AUC0-72 was (100 251.84±42 195.63) ng· h · mL-1 and (102 778.12±46 622.56) ng · h · mL-1;AUC0-∞was (105 221.44±48 385.47) ng·h·mL-1 and (108 360.52t53 614.41) ng·h·mL-1;and t1/2 was (13.67±5.51)h and (14.05 ± 6.16) h.The relative bioavailability was (99.01 ± 11.40)%.After logarithmic transformation,the 90% confidence intervals of Cmax,AUC0-72 and AUC0-∞ were 95.11%-105.02%,86.33%-111.13% and 86.89%-110.77%,respectively.No significant difference was found among the main pharmacokinetic parameters between the trial preparation and the reference preparation (P > 0.05) by ANOVA.No significant difference was found in tmax between the trial preparation and the reference preparation (P > 0.05) by nonparametric test.The two one-sided t-tests showed that the trial preparation and the reference preparation were bioequivalent.No adverse events were found or reported during the study.Conclusion The 2 gliclazide tablets are bioequivalent.
What problem does this paper attempt to address?